Abraxane Improves Survival Among Pancreatic Cancer Patients
Celegene Corp's drug Abraxane (paclitaxel protein-bound particles for injectable suspension) was found to be effective at improving overall survival among pancreatic cancer patients when combined with chemotherapy, according to results from the drug's phase III clinical trial. Even though Pancreatic cancer is a relatively uncommon form of cancer - making up only 2...Migraine Triggers Not As Powerful As We Think New Norovirus Strain Behind Recent Outbreaks In U.S.
